Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Estee Lauder Companies Inc (EL) vs Sanofi SA (SNY) Price & Performance

Estee Lauder Companies IncTrade

Price performance (Past 24H)

Key statistics

Estee Lauder Companies Inc vs Sanofi SA — how do they compare? Estee Lauder Companies Inc trades at $88 (market cap $31.76B), while Sanofi SA trades at $43.7 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3.3× Estee Lauder Companies Inc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

ELSNY
Market Cap
$31.76B$104.30B
Sector
Consumer StaplesHealth
52-Week High
$119.61$52.34
52-Week Low
$67.23$41.33
Enterprise Value
$37.93B$124.19B
Dividend Yield
1.59%5.55%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Estee Lauder Companies Inc

Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.

Read more on EL

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY